US Corporate Distress Financial Stress SEC Filings — June 29, 2026

29-06-2026

Korn Ferry (KFY) announced a definitive agreement to acquire AMS from OMERS Private Equity for approximately £850 million (~$1.1 billion), combining cash (~£659M/$881M) and stock (~£191M/$255M). The deal is expected to close in Q2 FY'27 and be immediately accretive to EPS in the first full year, creating a global talent and organizational consulting leader with over 16,000 colleagues. However, the acquisition carries integration risks and requires regulatory clearances, and the purchase price relies on a specific exchange rate that may fluctuate.

• · AMS was founded by Rosaleen Blair in 1996.
• · AMS serves clients across financial services, technology, healthcare, life sciences, consumer, industrial, and public sector markets.
• · The combined firm will place a professional in a job approximately every 90 seconds.
• · Korn Ferry is the Official Talent & Organizational Consulting Partner of LA28.
• · The conference call for investors is scheduled for June 29 at 8:30 a.m. EDT.

29-06-2026

U.S. GoldMining Inc. entered into a securities purchase agreement to sell 522,876 shares at $7.65 per share in a registered direct offering, expecting gross proceeds of $4.0 million. The offering is set to close on June 29, 2026, with net proceeds used for working capital and general corporate purposes.

• · The shares are offered under an effective shelf registration statement on Form S-3 (File No. 333-279435) filed on May 15, 2024, and declared effective on May 28, 2024.
• · The Purchase Agreement includes customary representations, warranties, and covenants, as well as indemnification for the Investor.
• · The legal opinion of Haynes and Boone, LLP regarding the validity of the shares is filed as Exhibit 5.1.

29-06-2026

Volato Group, Inc. entered into a Securities Purchase Agreement on June 28, 2026, to sell 11,038,767 shares of Class A common stock at $0.165 per share in a registered direct offering, expecting gross proceeds of approximately $1.82M. The offering is subject to NYSE American approval. Additionally, director Alan Gaines resigned on June 24, 2026, to avoid potential conflicts as the company explores AI and digital infrastructure transactions.

• · The offering is a registered direct offering without a placement agent or underwriter, so no underwriting discounts or commissions are paid.
• · The company agreed to a 30-day lock-up on issuing additional shares or filing registration statements (except for employee benefit plans) and a 9-month restriction on Variable Rate Transactions.
• · The Purchase Agreement includes customary representations, warranties, and indemnification provisions.
• · The offering is made under an effective shelf registration statement on Form S-3 (File No. 333-290219) filed on September 12, 2025 and declared effective on September 30, 2025.
• · Alan Gaines resigned as director effective June 24, 2026, following the termination of the merger agreement with M2i Global, Inc. on June 4, 2026.
• · The company stated its intent to seek potential transactions in the AI and digital infrastructure sector after the merger termination.

29-06-2026

Decoy Therapeutics, Inc. announced a PIPE financing with a single healthcare-focused institutional investor, expected to provide $3.5 million in upfront gross proceeds at $5.91 per share, with potential additional proceeds of up to $17.5 million from milestone-based warrants. The company intends to use net proceeds to advance its lead asset into clinical trials. The offering is expected to close on June 29, 2026.

• · Purchase price per share: $5.91
• · Series A warrant exercise triggers: shareholder approval and filing of Clinical Trial Application in EEA for Phase 1 trial
• · Series B warrant exercise triggers: shareholder approval and MHRA approval for Phase 2a human challenge trial in UK
• · Series C warrant exercise triggers: shareholder approval and public announcement of positive Phase 2a data from UK trial
• · Registration rights agreement: file resale registration statement within 15 days after closing, use best efforts for effectiveness within 90 days (or 90 days after full review)
• · Placement agent: Curvature Securities LLC
• · Offering exempt from registration under Section 4(a)(2) and/or Regulation D

29-06-2026

Allegiant Travel Company announced early tender results for its 7.250% Senior Secured Notes due 2027, receiving valid tenders for $377,534,000 of the $403,009,000 outstanding principal amount (93.68% participation) by the Early Tender Deadline. The company also obtained consents from a majority of holders to eliminate most restrictive covenants and reduce the redemption notice period to 3 business days. However, the tender offer is contingent on the company successfully completing one or more debt financings, and any notes not purchased may be redeemed on August 15, 2026 at par.

• · The tender offer and consent solicitation were launched on June 9, 2026 via an Offer to Purchase and Consent Solicitation Statement.
• · The Proposed Amendments eliminate most restrictive covenants and certain events of default, and reduce the minimum redemption notice period from 30 days to 3 business days.
• · Holders who tender after the Early Tender Deadline but by the Expiration Time (July 9, 2026) will receive only the Tender Offer Consideration of $955 per $1,000 principal, not the Early Tender Premium.
• · The company may redeem any remaining notes on August 15, 2026 at 100% of principal plus accrued interest, but has no obligation to do so.
• · The tender is subject to the company successfully completing one or more debt financings.
• · Barclays Capital Inc. is acting as dealer-manager and solicitation agent.

29-06-2026

Art's-Way Manufacturing Co., Inc. entered into a $500,000 revolving credit facility with Bank Midwest on June 22, 2026, to fund deposits for a new fiberoptic laser and crane system for its Agricultural Products Segment. The facility is secondary to the company's existing $4,000,000 line of credit and will be converted to 15-year term debt upon equipment delivery, estimated in 16-18 weeks. The initial interest rate is 6.225% per annum, with a maturity date of March 30, 2027.

• · The Reserve Line of Credit matures on March 30, 2027.
• · The equipment delivery and installation is estimated in 16-18 weeks.
• · The term debt will have a 15-year term at an estimated rate of 6.50% per annum, which may fluctuate with market rates.
• · The Reserve Line of Credit is secondary to the existing $4,000,000 line of credit and will be utilized upon that line reaching capacity.

29-06-2026

Rockwell Medical, Inc. filed a certificate of amendment to effect a 1-for-10 reverse stock split, effective July 1, 2026, approved by stockholders at the June 12, 2026 annual meeting. The split aims to consolidate outstanding shares and maintain Nasdaq listing compliance, with no change in par value or trading symbol. No fractional shares will be issued; cash will be paid in lieu of fractions.

• · Reverse stock split ratio is 1-for-10.
• · Effective time is 12:01 a.m. Eastern Time on July 1, 2026.
• · Common stock will trade on a split-adjusted basis from July 1, 2026, under symbol RMTI.
• · New CUSIP number: 774374409.
• · No fractional shares will be issued; cash payment based on closing price on June 30, 2026.
• · Proportionate adjustments will be made to equity awards, preferred stock conversion price, and warrants.
• · Authorized shares after split: 170,000,000 common shares and 2,000,000 preferred shares.

29-06-2026

Theravance Biopharma has entered into a definitive agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash, representing an equity value of approximately $929 million. Shareholders will also receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future monetization of ampreloxetine over ten years. The transaction, which follows a comprehensive strategic review, is expected to close in the second half of 2026 and represents a 22% premium to the company's closing price on March 3, 2026, and a 10% premium to its volume-weighted average price since that date.

• · The CVR entitles shareholders to 80% of net proceeds from any future license, divestiture or other monetization of ampreloxetine over the next ten years, with the remaining 20% to Zymeworks.
• · If a monetization transaction for ampreloxetine is not executed by closing, a designee from Theravance Biopharma will explore opportunities for 12 months post-closing.
• · The Strategic Review Committee was formed in 2024 and oversaw actions including the $225 million monetization of the TRELEGY royalty interest in 2025.
• · The transaction is subject to shareholder approval, regulatory approvals, and other customary closing conditions.
• · Advisors: Lazard (lead financial advisor), Evercore (financial advisor), Skadden (legal counsel) for Theravance; Kirkland & Ellis (legal), Matheson (tax counsel), TD Cowen (financial advisor on OMERS royalty note), MTS Health Partners (financial advice) for Zymeworks.

29-06-2026

Honeywell Aerospace Inc. reported FY 2025 net sales of $17,404 million, up 13% from $15,445 million in FY 2024, with net income attributable to Honeywell Aerospace declining 4.6% to $2,687 million from $2,817 million. While full-year organic sales grew 12%, Q4 2025 net income fell sharply to $430 million from $571 million in Q4 2024, and the Engines & Power Systems segment posted a segment loss of $57 million in Q4 2025 due to a $373 million Flexjet-related litigation settlement.

• · FY 2025 total segment profit was $4,085 million, up from $3,708 million in FY 2024.
• · FY 2025 Adjusted EBIT was $4,458 million, up from $3,708 million in FY 2024.
• · Q4 2025 Engines & Power Systems segment profit was a loss of $57 million, compared to a loss of $129 million in Q4 2024.
• · FY 2025 Electronic Solutions segment profit was $1,988 million, up 4% from $1,912 million in FY 2024.
• · FY 2025 Control Systems segment profit was $1,523 million, up 24.2% from $1,226 million in FY 2024.
• · FY 2025 Engines & Power Systems segment profit was $691 million, essentially flat compared to $692 million in FY 2024.
• · FY 2025 organic sales growth was 12%, with Engines & Power Systems leading at 21%, Control Systems at 10%, and Electronic Solutions at 5%.
• · Q4 2025 organic sales growth was 20%, driven by Engines & Power Systems at 62% (partly due to the low base from the Bombardier adjustment in Q4 2024).
• · Environmental remediation expenses totaled $389 million in FY 2025, up from $235 million in FY 2024.
• · Transaction costs were $269 million in FY 2025, up from $0 in FY 2024.

29-06-2026

Rocket Lab (RKLB) will acquire Iridium (IRDM) for $54 per share in a cash-and-stock deal, implying an ~$8.0B enterprise value. The transaction combines Rocket Lab's launch and satellite manufacturing with Iridium's global L-band network and 2.55M+ subscribers, creating a vertically integrated space company. Iridium delivered $871.7M revenue and $495M OEBITDA (57% margin) in 2025, providing recurring cash flow; however, the deal is not expected to close until mid-2027 and remains subject to stockholder and regulatory approvals.

• · The cash component is $27.00 per share; the stock component is subject to an exchange ratio with a collar banded from $67.50 to $112.50.
• · Rocket Lab has received commitments for a $3.6B 364-day senior secured bridge term loan facility from Deutsche Bank and Wells Fargo.
• · Each Iridium director holding shares has entered into a voting agreement to support the transaction.
• · The transaction has been unanimously approved by the boards of both companies.
• · Iridium's 2025 OEBITDA margin was 57%.
• · Iridium supports more than 2.55 million active subscribers worldwide.

29-06-2026

Shoulder Innovations, Inc. (NYSE: SI) closed two new credit facilities totaling up to $50 million with Stifel Venture Banking, refinancing its existing debt with improved terms. The facilities include a $15 million fully funded term loan (interest-only through June 2029, maturing June 2031) and a $30 million undrawn line of credit with a $5 million accordion feature (maturing June 2029). The refinancing does not result in additional indebtedness or warrants, providing additional working capital capacity and financial flexibility.

• · Term loan interest rate: greater of prime rate minus 0.75% or 5.00%
• · Line of credit interest rate: greater of prime rate or 5.00%
• · Term loan is interest-only through June 30, 2029, and matures in June 2031
• · Line of credit matures in June 2029
• · No additional indebtedness or warrants at close
• · Company is a commercial-stage medtech firm focused on shoulder surgical care

29-06-2026

Martin Marietta Materials announced a definitive agreement to acquire Lhoist North America for $13.5 billion in cash and stock, expected to close in the second half of 2026. The deal will make Martin Marietta the leading U.S. lime and limestone producer, adding 20 quarries, 45 distribution terminals, and over 2 billion tons of reserves. The transaction is expected to be accretive to earnings and margins in the first full year after closing, with $85 million in annual run-rate cost synergies, but will increase net leverage to approximately 3.7x at closing.

• · The Berghmans family will have the right to appoint one director and one observer to Martin Marietta’s Board of Directors.
• · Martin Marietta expects Combined Net Leverage ratio to be approximately 3.7x at closing, with a target to reduce below 2.5x within 24 months.
• · The transaction is expected to close in the second half of 2026, subject to regulatory approvals.
• · Goldman Sachs provided fully committed debt financing for the transaction.
• · The conference call will be held at 8:30 a.m. Eastern Time on June 29, 2026.

29-06-2026

Zymeworks Inc. has entered into a definitive agreement to acquire Theravance Biopharma, Inc. for $17.00 per share, totaling approximately $929 million in cash consideration, adding YUPELRI® (revefenacin) to its portfolio. The acquisition is financed primarily through a $350 million non-recourse note from OMERS Life Sciences and Zymeworks' existing cash, with the transaction expected to close in the second half of 2026. While the deal is expected to be accretive to earnings and cash flow, generating ~$60 million annualized cash flow from YUPELRI® profit share, Zymeworks will contribute $219 million in cash at close and expects a $100 million milestone in Q1 2027 to offset outlay, with the company also continuing a share repurchase program for up to $125 million.

• · YUPELRI has been marketed in the U.S. since 2019 through a collaboration between Viatris and Theravance Biopharma.
• · Settlements reached with all YUPELRI generic filers for an April 2039 licensed launch date.
• · Theravance Biopharma eligible for $125M in commercial milestone payments from Viatris based on U.S. net sales.
• · Zymeworks will retain ~$2.5B in Irish tax attributes from Theravance Biopharma.
• · Zymeworks plans to complete Theravance Biopharma's organizational restructuring to reduce R&D and G&A costs.
• · Transaction expected to close in second half of 2026.
• · Zymeworks has repurchased 1,437,073 shares at an average price of $24.63 per share as of June 29, 2026.

29-06-2026

Barrel Energy Inc. filed an 8-K on June 29, 2026, disclosing amendments to its Certificate of Designation, which modifies the rights of security holders. The filing includes changes to the terms of previously designated series of preferred stock, potentially affecting conversion ratios, voting rights, or liquidation preferences.

• · Filing relates to Items 3.03 (material modification to security holder rights) and 5.03 (amendments to articles of incorporation or bylaws).
• · The amendment affects a series of preferred stock previously designated by the company.

29-06-2026

BillionToOne, Inc. entered into a 12-year lease for 62,659 square feet of office and lab space at 3260 Whipple Road, Union City, CA, to expand oncology laboratory capacity by more than three times and increase total facility space by ~16%. The lease, commencing around August 1, 2027, carries aggregate base rent of approximately $46.7 million, a 12-month rent abatement, and a $12.5 million tenant improvement allowance. The expansion is driven by test volumes exceeding the company’s plan over the past year, but the lease adds a long-term financial obligation and the company remains subject to forward-looking risks.

• · Lease commencement is anticipated on or about August 1, 2027, after substantial completion of tenant improvements.
• · The lease includes an option to extend for an additional 10 years at the then-prevailing market rate.
• · The company will pay its pro rata share of operating expenses, taxes, and assessments related to the premises.
• · The laboratory space will be dedicated to oncology products, more than tripling the current oncology-dedicated lab space.
• · The lease was entered into on June 23, 2026, and the 8-K was filed on June 29, 2026.

29-06-2026

Golub Capital Private Income Fund I entered into a second amended and restated side letter to its BANA Credit Facility on June 23, 2026, modifying the minimum utilization level for calculating the unused commitment fee through September 30, 2026. The amendment provides temporary relief on fee calculations, but no financial figures or performance metrics were disclosed in the filing.

• · The side letter was entered into on June 23, 2026, and filed on June 29, 2026.
• · The amendment modifies the minimum utilization level for unused commitment fee calculation through September 30, 2026.
• · The BANA Credit Facility was originally amended and restated on December 31, 2025.

29-06-2026

Golub Capital Private Income Fund S, through its subsidiary GPIF S Funding, entered into a second amended and restated side letter to its BANA Credit Facility on June 23, 2026. The amendment modifies the minimum utilization level for calculating the unused commitment fee through September 30, 2026. No financial figures or performance metrics were disclosed in this filing.

• · The side letter modifies the minimum utilization level for calculating the unused commitment fee through September 30, 2026.
• · The original credit agreement was amended and restated on December 31, 2025.

29-06-2026

Datavault AI Inc. entered a binding term sheet with Scilex Holding Company on June 24, 2026, for the proposed sale of 837 BTC held in a digital wallet for a total purchase price of $50 million. Scilex will make an initial $30 million payment, with the remaining $20 million paid in quarterly installments through December 31, 2028, in cash or securities at Scilex's discretion. However, the transaction is subject to a definitive agreement and numerous conditions, and there is no assurance it will be consummated, posing significant execution risk.

• · Scilex has discretion to pay the purchase price in cash, its common stock, or publicly traded securities of its subsidiaries.
• · The term sheet may be terminated by either party, and failure to reach a definitive agreement could lead to costly litigation.
• · Remaining $20 million is payable in quarterly installments starting Q4 2026 and ending December 31, 2028.

29-06-2026

Zimmer Biomet Holdings, Inc. entered into a Five-Year Revolving Credit Agreement dated June 26, 2026, with JPMorgan Chase Bank as administrative agent and a syndicate of lenders. The agreement provides for a $1.5 billion revolving credit facility for general corporate purposes and a $50 million letter of credit subfacility. The facility matures in five years and includes a financial condition covenant, incremental commitment provisions, and an extension option.

• · The credit agreement includes a financial condition covenant (Section 9.04) and a limitation on subsidiary indebtedness (Section 9.05).
• · The facility has an extension of maturity date provision (Section 2.05) and incremental commitment provisions (Section 5.05).
• · The agreement references a separate 364-Day Credit Agreement dated the same day.
• · The pricing grid is set forth in Annex I, and the initial commitments are listed in Schedule 2.01.

29-06-2026

FibroBiologics (FBLG) announced a private placement priced at-the-market under Nasdaq rules, with expected gross proceeds of $3.0 million upfront and potential additional proceeds of up to $6.0 million from the exercise of series A and series B warrants (each exercisable at $0.735 per share). The offering involves 4,081,633 shares (or pre-funded warrants) and corresponding warrants. However, there is no assurance any warrants will be exercised, and the company plans to use net proceeds for working capital and general corporate purposes, highlighting ongoing capital needs.

• · The series A warrants expire 5 years after the later of Stockholder Approval Date and effective date of the resale registration statement; series B warrants expire 18 months after the same trigger date.
• · The purchase price per share (and accompanying warrants) is $0.735.
• · The private placement is expected to close on June 29, 2026.
• · The offering is conducted under Section 4(a)(2) and/or Regulation D of the Securities Act; securities are unregistered and subject to a registration rights agreement.
• · The company has over 270 issued and pending U.S. and international patents.

29-06-2026

Cheetah Net Supply Chain Service Inc. (CTNT) and its sales agent AC Sunshine Securities LLC mutually terminated their Sales Agreement effective June 26, 2026, which had been in place since March 31, 2026. The termination eliminates the company's ability to issue and sell shares of Class A common stock through an at-the-market offering program under its existing S-3 registration statement. No amounts, fees, or expenses were due to the sales agent at termination, and no unsettled sales remain.

• · The Sales Agreement was originally dated March 31, 2026, meaning it was active for less than three months before termination.
• · The agreement related to the offer and sale of shares of Class A common stock, par value $0.0001 per share, under registration statement Form S-3 (File No. 333-281820).
• · Certain sections of the Sales Agreement survive termination, including Sections 7(g), 9, 10, 11(f), 16, and 17.
• · The termination was effective as of the close of business on June 26, 2026.

29-06-2026

Hertz Global Holdings has entered into a Share Lending Agreement with J.P. Morgan Securities LLC, under which Hertz will lend 37,037,037 shares of its common stock to J.P. Morgan in connection with the issuance of $350 million (plus up to $50 million over-allotment) of 6.75% Exchangeable Senior First-Lien Secured PIK Notes due 2030 by The Hertz Corporation. The non-cash loan fee is a nominal $0.01 per share (totaling ~$370,370). The agreement includes standard collateral provisions and restricts J.P. Morgan from borrowing shares that would cause its beneficial ownership to exceed 7.5% of outstanding common stock.

• · The Facility Termination Date is the earliest of October 1, 2030, three months after no Exchangeable Notes remain outstanding, or termination under Section 15.
• · The loan is contingent upon the closing of the initial issuance of the Exchangeable Notes occurring substantially contemporaneously.
• · Borrower’s Section 16 Percentage is capped at 7.5% of outstanding Common Stock.
• · Collateral must have Market Value at least equal to the Market Value of the Loaned Shares on the Closing Date.
• · Eligible Non-Cash Collateral includes U.S. Treasury bills and notes, and irrevocable letters of credit from qualifying banks.

29-06-2026

Athene Holding Ltd. entered into two new revolving credit agreements on June 26, 2026: a $1.75 billion (expandable to $2.50 billion) facility with Citibank maturing in 2031, and a $2.60 billion (expandable to $3.10 billion) 364-day facility with Wells Fargo maturing in 2027. These agreements replace prior facilities and include financial covenants requiring minimum consolidated net worth of $22.06 billion (Citi) and $26.23 billion (Wells), with debt-to-capitalization capped at 40%.

• · The Citi Credit Agreement replaces a prior agreement dated June 30, 2023.
• · The Wells Credit Agreement replaces a prior 364-day agreement dated June 27, 2025.
• · Citi Credit Agreement interest margins range from 0.875% to 1.500% for Term SOFR and 0.000% to 0.500% for Base Rate, based on debt rating.
• · Wells Credit Agreement interest margins range from 1.000% to 1.250% for Term SOFR and 0.000% to 0.250% for Base Rate, based on financial strength rating.
• · Citi Credit Agreement undrawn commitment fee ranges from 0.070% to 0.175%.
• · Wells Credit Agreement undrawn commitment fee ranges from 0.080% to 0.125%.
• · Both agreements include customary covenants restricting liens, fundamental changes, affiliate transactions, and business changes.
• · The Citi Credit Agreement has a maturity of June 26, 2031, with two possible 1-year extensions.
• · The Wells Credit Agreement matures June 25, 2027, with possible 364-day extensions or term-out conversion.

29-06-2026

GCI Liberty, Inc. (GLIBK) entered into Amendment No. 1 to its Ninth Amended and Restated Credit Agreement on June 29, 2026, securing $480 million in new financing: $155 million in Incremental Term A-1 Loans, $300 million in Incremental Term A-2 Loans, and $25 million in Incremental Revolving Commitments. The proceeds will fund the Quintillion Acquisition (purchase of Q Gateway Intermediate Holdings, LLC) and refinance existing debt, including the retirement of a portion of the 2028 Notes. The amendment also adds a new issuing bank and updates legal opinions and compliance certificates.

• · The amendment was executed under Section 2.13 of the Existing Credit Agreement dated March 25, 2025.
• · The Incremental Revolving Commitments are solely for Letters of Credit and cannot be drawn as Revolving Loans (except for reimbursement obligations).
• · The Quintillion Acquisition is governed by a Securities Purchase Agreement dated April 21, 2026.
• · Conditions for effectiveness include delivery of legal opinions from O'Melveny & Myers LLP, Dillon Findley & Simonian, P.C., and Moira Smith, as well as a solvency certificate and compliance with anti-money laundering regulations.
• · The amendment adds new classes of Term Loans and Revolving Loans, separate from existing classes.

29-06-2026

MediaAlpha entered into an agreement on June 25, 2026 to purchase Insignia's interest in its Tax Receivables Agreement (TRA) for $31.0 million in cash, a 55% discount to its estimated $68.7 million value. This reduces the company's total estimated TRA liability from $123.4 million to approximately $55.0 million as of June 30, 2026. The transaction was approved by disinterested directors and funded from subsidiary cash on hand and borrowing under its revolving credit facility.

• · The agreement is an Assignment, Assumption and Termination Agreement (the 'Agreement') entered into on June 25, 2026.
• · The purchase does not constitute a change of control or early termination under the TRA.
• · Remaining TRA payments will continue with respect to other counterparties.
• · To fund the payment, QLH made a pro rata distribution to its members, including certain directors and executive officers of the Company.
• · The Board approved the transaction, with a majority composed of independent and disinterested directors.

29-06-2026

Meritage Homes entered into a Twelfth Amendment to its Credit Agreement, increasing total commitments from $910M to $980M and extending the Class A Termination Date to June 24, 2031. The amendment also updates the minimum net worth test to $3,531,291,000 (down from $3,602,112,000) and adjusts certain interest rate definitions. No defaults were reported.

• · The amendment updates the Adjusted Daily Simple SOFR and Adjusted Term SOFR Rate definitions to include a 0.10% spread.
• · The L/C Commitment remains up to 100% of Total Commitment, with a specific Issuing Lender commitment of $370M as of June 24, 2026.
• · The amendment includes a reaffirmation of guarantees and no novation.

29-06-2026

Middleby announced that its soon-to-be-spun-off food processing subsidiary, Midera Food Processing, Inc., has entered into a $1.0 billion five-year credit agreement with Bank of America and other lenders, comprising a $750 million USD revolving credit facility and a $250 million multi-currency revolving credit facility. The spin-off remains on track for July 6, 2026, and the credit facility is intended to support Midera's acquisition-driven growth strategy as an independent public company. No negative or flat performance metrics were disclosed in this filing.

• · The spin-off is conditioned upon satisfaction or waiver of certain conditions as set forth in the Separation and Distribution Agreement filed with the SEC.
• · Midera's registration statement on Form 10 was declared effective by the SEC on June 17, 2026.
• · Midera is headquartered in Rosemont, Illinois.
• · The credit agreement has a five-year term.

29-06-2026

PennantPark Private Income Fund entered into an Amended and Restated Expense Limitation and Reimbursement Agreement with its investment adviser, PennantPark Private Income Fund Advisers LLC, on June 29, 2026. The amendment broadens the adviser's expense support from a limitation to a reimbursement structure, allowing the adviser to elect to pay certain specified expenses of the fund. The agreement includes a recoupment mechanism over a rolling three-year period and automatically terminates on September 30, 2027.

• · The Expense Support Agreement automatically terminates on September 30, 2027.
• · Expense Payments are eligible for recoupment over a rolling three-year period from the calendar quarter-end when made.
• · Reimbursement Payments are limited to the lesser of Excess Operating Funds in a quarter or the aggregate unreimbursed Expense Payments made within the prior three years.
• · The Investment Adviser may defer its right to receive Reimbursement Payments in any quarter.
• · Specified Expenses exclude Base Management Fee, Incentive Fee, brokerage costs, dividend/interest payments, taxes, extraordinary expenses, Organization and Offering Expenses, and indirect costs of investing in other investment companies.

29-06-2026

Verizon Master Trust filed an 8-K on June 29, 2026, disclosing entry into an Underwriting Agreement on June 25, 2026, for the issuance of $1,200,000,000 in Series 2026-2 Asset Backed Notes. The notes consist of four tranches: Class A-1a ($994,210,000 at 4.51%), Class A-1b ($75,000,000 at Compounded SOFR + 0.46%), Class B ($81,740,000 at 4.71%), and Class C ($49,050,000 at 4.85%). The filing also details related agreements to be executed on the closing date of June 30, 2026, including an Indenture and Account Control Agreement.

• · Underwriting Agreement entered into on June 25, 2026, with closing date scheduled for June 30, 2026.
• · The notes are secured by a pool of device payment plan receivables.
• · The filing includes various ancillary agreements such as the Indenture, Series 2026-2 Account Control Agreement, and Second Amended and Restated Asset Representations Review Agreement.
• · Form of Depositor Certification required by Item 601(b)(36) of Regulation S-K was filed.

29-06-2026

Andersen Group Inc. (ANDG) announced that its indirect subsidiary, Andersen Tax LLC, entered into a $50.0 million asset-based revolving credit facility with JPMorgan Chase Bank, N.A. on June 25, 2026. The facility matures in three years, bears interest at Term SOFR plus 175 basis points, and is secured by a first lien on all assets of the loan parties. The agreement includes a springing minimum fixed charge coverage ratio of 1.00x and various covenants, but no early termination fee.

• · The Credit Agreement includes a springing minimum fixed charge coverage ratio of 1.00x, tested monthly on a trailing twelve-month basis, effective when borrowing availability falls below 25% of the line cap (with a $6.0M floor).
• · For the trailing twelve-month testing periods through November 2026, the FCCR definition excludes specialty allocated income, pre-IPO book income discretionary distributions, and redemptions.
• · Permitted foreign acquisitions during drawn or undrawn periods are capped at $15M per transaction and $75M in aggregate per annum.
• · Investments in non-Loan Party subsidiaries up to $10M in aggregate do not require satisfaction of payment conditions.
• · Prepayment events (asset dispositions >$10M, casualty losses, equity issuances, debt incurrence outside baskets) require mandatory paydown only if availability falls below 25% of the line cap (with a $6.0M floor).
• · Collateral reporting escalates to weekly if availability falls below 20% of the line cap (with a $4.5M floor).
• · The subordination agreement permits regularly scheduled interest payments to Andersen Aggregator LLC at up to 7.63% per annum.

29-06-2026

KKR Infrastructure Conglomerate LLC increased its revolving credit facility by $250 million to $1,550 million through lender joinder agreements, with an accordion feature allowing up to $2.0 billion. The company also declared distributions across six share classes, with Class I, R, and F shares receiving $0.3300 per share, Class D $0.3108, Class U $0.2649, and Class S $0.2648. The filing shows no negative or flat performance metrics, as it focuses on financing and distribution actions.

• · The credit agreement was originally dated April 3, 2024, and matures on April 3, 2028, unless earlier terminated or accelerated upon default.
• · The joinders were entered into by indirect subsidiaries of the company.
• · Distributions are payable to holders of record as of June 30, 2026, and will be paid on or about July 27, 2026.
• · Distributions may be paid in cash or reinvested in shares under the company's distribution reinvestment plan.

29-06-2026

TOMI Environmental Solutions (TOMZ) announced a definitive merger agreement with Carbonium Core, a U.S. developer of graphite and rare earth metals for nuclear and defense applications. The transaction will result in Carbonium shareholders owning approximately 90% of the combined company, positioning TOMI as a pure-play on the nuclear renaissance driven by AI power demand. However, the merger is subject to conditions including a minimum $10 million financing and Nasdaq listing approval, and TOMI's existing disinfection business will be diluted to a minority stake.

• · The merger is expected to close in Q3 2026, subject to conditions including a minimum $10 million financing and Nasdaq listing application approval.
• · Carbonium shareholders will initially receive common stock (limited to avoid Nasdaq stockholder approval) and non-voting Preferred Stock; upon stockholder approval, Preferred Stock converts to common stock, giving them ~90% ownership.
• · Carbonium's purification technology is licensed from Oak Ridge National Laboratory.
• · The combined company plans to incorporate carbonium graphene into TOMI's disinfection robotics and redesign biosafety drones using carbonium core, graphene, and lithium components.
• · TOMI's existing business (decontamination/disinfection) will become a minority part of the combined entity.

29-06-2026

FS KKR Capital Corp. closed a $150 million issuance of cumulative convertible perpetual preferred stock to KKR Alternative Assets L.P., with proceeds for general corporate purposes including share repurchases or debt repayment. The preferred stock pays 5.00% cash dividends (or 7.00% PIK at the company's option), with a 5.5-year step-up and initial conversion price of $18.83 per share. The offering was unregistered under Section 4(a)(2) of the Securities Act.

• · The preferred stock ranks junior to all existing indebtedness and senior to common stock.
• · After three years, the company may redeem the preferred stock with common shares if the 30-day VWAP is at or above the conversion price.
• · Holders can convert after six months; after six years or certain events, the preferred stock may be redeemable in cash.
• · Holders vote on an as-converted basis and elect two board members; majority holders can require redemption upon change of control.
• · The offering was exempt from registration under Section 4(a)(2) of the Securities Act.

29-06-2026

Scilex Holding Company entered a binding term sheet on June 24, 2026, to purchase 837 Bitcoin from Datavault AI Inc. for $50 million, with an initial payment of $30 million and the balance in quarterly installments through December 31, 2028. Payment may be made in cash, shares of Scilex common stock, or publicly traded securities of its subsidiaries. However, the transaction is subject to finalizing a definitive agreement and numerous conditions, and there is no assurance the purchase will close.

29-06-2026

Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP on June 23, 2026, for the sale of a Note and Commitment Shares in a private placement under Section 4(a)(2) and Rule 506(b). The agreement includes covenants such as D&O insurance purchase within 60 days of closing (18-month coverage with 2-year tail), transfer agent instructions, and mandatory arbitration in Orange County, CA. The company faces a $3,000 per day liquidated damages penalty for failure to timely file material non-public information via an 8-K. No financial terms of the Note (e.g., principal amount, interest rate) were disclosed in this excerpt.

• · Company must purchase D&O insurance within 60 calendar days of Closing for a period of 18 months after Closing, with two years of tail coverage.
• · Company must provide corporate resolutions and issuance approvals to its transfer agent within 6 hours of each conversion of the Note.
• · If the Company breaches any covenants in Section 4, it is considered an Event of Default under Section 3.3 of the Note.
• · Exclusive venue for arbitration of Claims is Orange County, California; the Company consents to personal jurisdiction there.
• · The Company acknowledges that the Buyer is not a broker-dealer under the Securities Exchange Act of 1934.

29-06-2026

Globe Life Inc. entered into a Third Amended and Restated Credit Agreement and an Amended and Restated Term Loan Agreement on June 26, 2026. The credit facility's maturity was extended to June 2031 and the term loan principal was increased from $250M to $450M with maturity extended to June 2029. Both agreements also changed the administrative agent from Bank of America to Wells Fargo.

• · The credit agreement maturity was extended from March 29, 2029 to June 26, 2031.
• · The term loan maturity was extended from August 15, 2027 to June 26, 2029.
• · The administrative agent for both agreements changed from Bank of America to Wells Fargo.
• · The filing does not disclose any financial impact, revenue changes, or performance metrics.

29-06-2026

Contango ORE, Inc. provided project updates across its portfolio in Alaska and British Columbia, including commencement of the Lucky Shot surface drill program (6,800m planned), ongoing permitting for the Johnson Tract project, and a Kitsault Valley drill program with over 14,000m completed. The company also fully delivered its remaining 11,000 oz of 2026 gold hedge obligations ahead of schedule, increasing its gold price exposure. However, no assay results have been released yet, and the company continues to carry 15,000 oz of 2027 hedge obligations.

• · The company holds a 30% interest in Peak Gold JV, with 70% owned by KG Mining (Kinross).
• · Permitting for Johnson Tract includes six actions completed and remains on schedule.
• · Kitsault Valley updated Mineral Resource Estimate (MRE) is expected by late July.
• · First assay results from Kitsault Valley are expected in Q3.
• · Geotechnical drilling and construction of a 2.6-mile road on CIRI land are planned this summer for Johnson Tract.
• · The company has 15,000 oz of gold hedge contracts remaining for delivery in first half of 2027.

29-06-2026

PVH Corp. entered into a new Credit Agreement dated June 24, 2026, with Bank of America as Administrative Agent and a syndicate of lenders including JPMorgan, Barclays, Citibank, Goldman Sachs, Mizuho, and others. The agreement establishes Tranche A Euro Term Loans, Revolving Loans, Swing Line Loans, and Letters of Credit, with PVH Corp. as U.S. Borrower and PVH B.V. as Euro Borrower. The filing does not disclose specific commitment amounts, interest rates, or financial covenant thresholds, limiting immediate quantitative assessment.

• · The Credit Agreement includes provisions for Incremental Facilities, Additional Borrowers, and Extension of Maturity Date.
• · Negative covenants include restrictions on Liens, Mergers, Indebtedness, and a Financial Covenant (Section 6.04).
• · The agreement contains standard representations, warranties, affirmative and negative covenants, events of default, and guaranty provisions.
• · The filing is an 8-K with Items 1.01, 1.02, 2.03, and 9.01, indicating entry into a material definitive agreement and creation of a direct financial obligation.
• · No specific dollar amounts, interest rates, or financial covenant ratios are disclosed in the exhibit.

29-06-2026

4D Molecular Therapeutics entered into a loan and security agreement with Hercules Capital for up to $200.0 million in term loans, with an initial $20.0 million drawn at closing. The facility includes multiple tranches with varying availability conditions and interest rates, and matures on June 1, 2031. The agreement contains financial covenants including minimum cash requirements and a performance covenant tied to FDA approval and revenue milestones.

• · The agreement is secured by substantially all of the company's assets, including intellectual property.
• · Interest rate for Tranche 1A is the greater of prime rate plus 2.00% or 8.75%.
• · Interest rate for other tranches is the greater of prime rate plus 2.50% or 9.25%.
• · Interest rate on any advance cannot exceed the initial rate by more than 0.75%.
• · Minimum cash covenant is not tested on days when market capitalization exceeds seven times outstanding obligations.
• · Performance covenant is tested nine months after FDA approval of lead product candidate and aggregate borrowings of at least $75 million.
• · Performance covenant requires satisfaction of at least one of three conditions: market cap >$750M with cash >=50% of obligations, cash >=125% of obligations, or trailing six-month net product revenue >=70% of forecast.
• · Tranche 1B is available until June 15, 2027.
• · Tranche 5 is available solely at Hercules' discretion.

29-06-2026

Rocket Lab (RKLB) announced a definitive agreement to acquire Iridium Communications (IRDM) for $54 per share in a cash-and-stock transaction, implying an enterprise value of approximately $8.0 billion. The deal creates a fully vertically integrated space company combining Rocket Lab's launch and satellite manufacturing with Iridium's global LEO network, L-band spectrum, and 2.55 million subscribers. Iridium delivered $871.7M revenue and $495M OEBITDA (57% margin) in 2025, providing substantial recurring cash flow, though the acquisition is not expected to close until mid-2027 and carries integration and regulatory risks.

• · The exchange ratio collar is banded from $67.50 to $112.50 per Rocket Lab share.
• · Rocket Lab has received commitments for a $3.6B 364-day senior secured bridge term loan facility from Deutsche Bank and Wells Fargo.
• · The transaction has been unanimously approved by the boards of directors of both companies.
• · Each director of Iridium holding shares has entered into a voting agreement to support the transaction.
• · The acquisition is expected to close in mid-2027, subject to Iridium stockholder approval and regulatory approvals.
• · Iridium's 2025 OEBITDA margin was 57%.
• · Iridium supports more than 2.55 million active subscribers worldwide.

29-06-2026

SandRidge Energy, Inc. (NYSE: SD) announced a definitive agreement to acquire producing assets and leasehold interests in the Cherokee Play (Mid-Continent) for $65 million in cash, with potential earn-outs up to $6 million based on WTI prices. The acquisition includes ~3.0 MBoed net production (43% oil), ~7,000 net acres, interests in 21 wells, and eight proven development locations, expected to be immediately accretive to production, EBITDA, and free cash flow. The transaction has a May 1, 2026 effective date and is expected to close in Q3 2026, funded with cash on hand.

• · The acquisition is expected to be immediately accretive to production, EBITDA, and free cash flow.
• · SandRidge plans to fund the transaction with cash on hand and maintain a meaningful cash balance post-close.
• · The company has a record of more than four years without a recordable safety incident.
• · This is the second sizeable asset acquisition in the Cherokee Play for SandRidge.

29-06-2026

Ocean Power Technologies (OPTT) announced that its Board unanimously approved an amendment and restatement of its Section 382 Tax Benefits Preservation Plan, extending the plan's expiration from June 29, 2026 to June 29, 2029. The plan is designed to protect the company's net operating loss carryforwards (NOLs) and other tax attributes by deterring any single investor or group from acquiring 4.99% or more of OPTT's outstanding common stock, which could otherwise trigger an ownership change under Section 382 of the Internal Revenue Code and substantially limit the company's ability to use its NOLs. The amendment will be submitted for stockholder ratification at the 2026 Annual Meeting, the date of which has not yet been announced.

• · The original Tax Benefits Preservation Plan was dated June 29, 2023 and was ratified by stockholders at the 2023 Annual Meeting.
• · The plan is intended to reduce the likelihood of an ownership change under Section 382 of the Internal Revenue Code, but cannot ultimately prevent such an event.
• · OPT plans to file additional reports on Form 8-K and Form 8-A/A with the SEC regarding the amendment.
• · The company's headquarters are in Monroe Township, New Jersey, with an additional office in Richmond, California.

29-06-2026

Emergent BioSolutions secured a $52.7 million contract modification from the U.S. Department of Health and Human Services (ASPR) to supply ACAM2000® vaccine, ancillaries, and diluent replacement lots for smallpox and mpox preparedness. Deliveries begin June 2026. This follows recent regulatory approvals in Saudi Arabia and Singapore for ACAM2000® against smallpox and mpox. No negative or flat financial metrics are reported in this filing.

• · The contract modification is under an existing 10-year contract (75A50119C00071) with ASPR.
• · ACAM2000® carries a boxed warning for serious complications including myocarditis, pericarditis, encephalitis, and fetal death.
• · Common adverse reactions include inoculation site symptoms, lymphadenitis, malaise, fatigue, fever, myalgia, and headache.

29-06-2026

Barings Private Credit Corporation entered into a First Amendment to its Amended and Restated Senior Secured Revolving Credit Agreement, dated June 24, 2026, with Sumitomo Mitsui Banking Corporation as Administrative Agent and Collateral Agent. The amendment adds new lenders, adjusts commitments, and modifies certain terms of the existing credit agreement. No financial amounts or performance metrics are disclosed in this filing.

• · The amendment is dated June 24, 2026, and filed as an 8-K on June 29, 2026.
• · New lenders joined the facility, and certain existing lenders received new classes of commitments or became Swingline Lenders.
• · The amendment includes a reaffirmation of guarantees by subsidiary guarantors.
• · No default was continuing as of the First Amendment Effective Date.
• · The governing law is the State of New York.